Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Anika Therapeutics ( (ANIK) ) has issued an announcement.
Anika Therapeutics reported a strong start to 2026, with first-quarter revenue on April 29, 2026 rising 13% year over year to $29.6 million, driven by double-digit growth in both its Commercial and OEM channels and a gross margin improvement to 64.2%. Adjusted EBITDA climbed to $4.3 million from $0.1 million as operational transformation, lean manufacturing initiatives and targeted investments boosted profitability, even as operating expenses increased due to one-time severance, while the company completed a $15 million share repurchase on April 10, 2026 and prepared for a smaller, seven-member board following the resignations of directors Glenn Larsen and William Jellison at the 2026 annual meeting.
Business highlights for the quarter included 9% growth in international osteoarthritis pain management revenue to $8.9 million and robust momentum for the Integrity regenerative solution, which saw U.S. procedures rise 35% and generated $1.8 million in sales. The OEM channel benefited from favorable order timing and solid demand for products such as Monovisc, the company ended March 31, 2026 with $41 million in cash and cash equivalents, and it reaffirmed its full-year 2026 guidance for modest top-line growth and adjusted EBITDA margins between 5% and 10%, underscoring confidence in its ongoing operational and portfolio strategy.
The most recent analyst rating on (ANIK) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Anika Therapeutics stock, see the ANIK Stock Forecast page.
Spark’s Take on ANIK Stock
According to Spark, TipRanks’ AI Analyst, ANIK is a Neutral.
ANIK scores 60 primarily due to improving revenue and cash-flow trends alongside a low-leverage balance sheet, supported by constructive 2026 guidance and profitability/cost-improvement actions. The score is held back by ongoing net losses and earnings volatility, stretched technical momentum (overbought signals), and regulatory/OEM-channel risks highlighted on the call.
To see Spark’s full report on ANIK stock, click here.
More about Anika Therapeutics
Anika Therapeutics, Inc., based near Boston, is a global leader in the design, development, manufacturing and commercialization of hyaluronic acid innovations. The company focuses exclusively on osteoarthritis pain management and orthopedic regenerative solutions, partnering with clinicians to deliver a differentiated product portfolio aimed at improving patient outcomes worldwide.
Average Trading Volume: 141,415
Technical Sentiment Signal: Hold
Current Market Cap: $212.4M
See more data about ANIK stock on TipRanks’ Stock Analysis page.